SI
RPRX icon

Sava Infond’s Royalty Pharma RPRX Stock Holding History

Sava Infond’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$951K Sell
16,960
-1,900
-10% -$98.9K 0.07% 109
2026
Q1 		$905K Sell
18,860
-4,340
-19% -$190K 0.13% 108
2025
Q4 		$896K Buy
23,200
+2,200
+10% +$83.9K 0.12% 104
2025
Q3 		$741K Hold
21,000
– – 0.11% 111
2025
Q2 		$757K Hold
21,000
– – 0.12% 104
2025
Q1 		$654K Hold
21,000
– – 0.12% 113
2024
Q4 		$536K Buy
+21,000
New +$557K 0.09% 117

Other funds holding RPRX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AIM
Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
KMC
Kirr Marbach & Co Columbus, Indiana $594M AUM 34% 1-Year Est. Return
SMDAM
Sumitomo Mitsui DS Asset Management Tokyo, Japan $14.5B AUM 37.68% 1-Year Est. Return
TPM
Triasima Portfolio Management Montreal, Quebec, Canada $740M AUM 69.74% 1-Year Est. Return

Sava Infond's RPRX Position: Q2 2026 in Review

Sava Infond reduced its Royalty Pharma (RPRX) stake by 10% in Q2 2026, selling an estimated $98.9K and leaving 16,960 shares worth $951K. The position accounts for 0.07% of the portfolio, ranked #109.

Sava Infond first reported a position in RPRX in Q4 2024 and has held it in 7 quarters since. 75 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Sava Infond held 16,960 shares of Royalty Pharma worth $951K as of Q2 2026.
  • Sava Infond sold 1,900 Royalty Pharma shares in Q2 2026, an estimated $98.9K.
  • Royalty Pharma made up 0.07% of Sava Infond's portfolio in Q2 2026, its #109 holding.
  • Sava Infond first reported a position in Royalty Pharma in Q4 2024 and has held it in 7 quarters since.
  • 75 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Sava Infond's 13F filing for Q2 2026, filed 16 Jul 2026.